Endocrine Abstracts

Background: Neuroendocrine tumor (NET) patients with diminished SSTR2 expre-ssion are not eligible for any type of SSTR2-specific imaging or treatment. Herein, we propose to epigenetically enhance and enable somatostatin receptor type 2 (SSTR2)-targeted theranostics for patients with NETs. Specifically, we have found that simultaneous inhibition of DNA methylation and his-tone de-ace-tylation enhanced SSTR2 expression and in vitro binding of [68Ga]DOTATATE....

Background: Patients with neuroendocrine tumors (NETs) have a 5-year survival rate of 30-60%. Surgery, and newly approved ‘tar-geted radionuclide therapy (TRT)’ with [177Lu]DOTATATE, are the only curative options for patients with NETs. TRT is limited to pa--tients that have high levels of somatostatin receptor subtype 2 (SSTR2) and can im-prove the survival of patients with low-grade tumors, but has little effect on high-grade NETs that express low SSTR2 ...

Background: Current theragnostic techniques for pancreatic neuroendocrine tumors (pNETs) exploit the overexpression of somatostatin receptors (SSTRs) on the cell surface. However, approximately 25% of low-grade and most high-grade pNETs do not express SSTRs, requiring alternative theranostics. Calreticulin (CALR) is a protein linked to reticular calcium homeostasis and immunogenic cell death. Upon sufficient cellular insult, CALR translocates from the endoplasmic reticulum (ER...